Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia

Field, Emma; Vally, Hassan; Grimwood, Keith; Lambert, Stephen B.

doi:10.1542/peds.2010-0443

Cited by 111 publications

(71 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Australia, a retrospective case-control study determined that the efficiency of the vaccine to protect against hospitalization during rotavirus outbreaks in native children was 57.1% with 1 dose of the vaccine and 84.5% with 2 doses 16 .…”

Section: Discussionmentioning

confidence: 99%

Intervention analysis of introduction of rotavirus vaccine on hospital admissions rates due to acute diarrhea

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intervention analysis of introduction of rotavirus vaccine on hospital admissions rates due to acute diarrhea

et al. 2014

View full text Add to dashboard Cite

show abstract

“…популяционного эффекта, то в Финляндии, где массовая вакцинация против РВИ была начата в 2009 г., а охват вакцинацией составил 95-97%, было выявлено снижение частоты госпитализации по поводу РВИ у детей старших возрастных групп, не подлежащих вакцина-ции, на 54-75%, а частоты амбулаторных посещений по поводу РВИ -на 30-79% [17]. Развитие популяцион-ного эффекта после начала массовой вакцинации про-тив РВИ было продемонстрировано также в Австрии, Бельгии, Великобритании и ряде других стран [18][19][20][21][22][23].…”

Section: One Of the Main Causes Of The Incidence Of Intestinal Infectunclassified

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Рудакова¹,

Харит²,

Podkolzin³

et al. 2017

Pediatr. farmakol.

View full text Add to dashboard Cite

“…2 Vaccine efficacy of these rotavirus vaccines in high income countries with low child mortality has consistently been shown to be between 85-100% against severe rotavirus disease, [3][4][5][6] with significantly lower vaccine efficacy (39-77%) in low income countries with high child mortality. [7][8][9] Similarly, vaccine effectiveness against severe rotavirus disease in postlicensure studies have shown greater protection in high income countries (89-100% in Australia and USA), [10][11][12] compared with low or middle income countries (40-76% in Brazil, El Salvador and Nicaragua). [13][14][15][16] Several hypotheses have been suggested to explain the difference in vaccine efficacy between lower and higher-income countries, including maternal antibodies acquired via breast milk or transplacentally.…”

Section: Introductionmentioning

confidence: 99%

Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand

Chen

Kirkwood

Bines

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident.Methods: Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected »4 weeks, »20 weeks and »28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression.Results: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05).Conclusions: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants.

show abstract

Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia

Cited by 111 publications

References 27 publications

Intervention analysis of introduction of rotavirus vaccine on hospital admissions rates due to acute diarrhea

Intervention analysis of introduction of rotavirus vaccine on hospital admissions rates due to acute diarrhea

Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand

Contact Info

Product

Resources

About